Stage IV Colorectal Cancer Clinical Trial
Official title:
Glutamine PET Imaging of Colorectal Cancer
The clinical trial studies how well 11C-glutamine and 18F-FSPG positron emission tomography (PET) imaging works in detecting tumors in patients with metastatic colorectal cancer compared to standard imaging methods such as magnetic resonance imaging (MRI) or computed tomography (CT) scanning.
PRIMARY OBJECTIVES: I. To establish and validate a 11C-glutamine (11C-Gln) and fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) PET image guided gene signature to predict response to EGFR-targeted therapy in patients with advanced wild-type RAS colorectal cancer (CRC). OUTLINE: Patients receive 11C-glutamine intravenously (IV) and undergo PET imaging over 120 minutes. Beginning 2 hours to 7 days after 11C-glutamine PET, patients receive fluorine F 18 L-glutamate derivative BAY94-9392 IV and also undergo PET imaging over 120 minutes. During each of the 11C-Glutamine and 18F-FSPG PET/CT scans, venous blood draws will be performed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01704703 -
Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
|
Phase 2 | |
| Terminated |
NCT02960282 -
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
|
||
| Completed |
NCT01998152 -
Individualized Nutritional Counselling During Chemotherapy for Colorectal Cancer (COLONUT)
|
N/A | |
| Not yet recruiting |
NCT06287723 -
French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)
|
||
| Completed |
NCT03005002 -
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
|
Phase 1 | |
| Completed |
NCT03095781 -
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer
|
Phase 1 | |
| Terminated |
NCT03111823 -
Exercise Program During Chemotherapy in Metastatic Colorectal Cancer
|
N/A | |
| Active, not recruiting |
NCT04267575 -
Canady Helios Cold Plasma Scalpel Treatment at the Surgical Margin and Macroscopic Tumor Sites
|
N/A | |
| Recruiting |
NCT03368963 -
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
| Active, not recruiting |
NCT01271582 -
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
|
Phase 4 | |
| Active, not recruiting |
NCT03800602 -
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05631574 -
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT03112668 -
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
|
N/A | |
| Terminated |
NCT01550510 -
Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02919644 -
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.
|
Phase 2 | |
| Completed |
NCT03373188 -
VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer
|
Phase 1 | |
| Terminated |
NCT04044430 -
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
|
Phase 1 | |
| Completed |
NCT05025748 -
Ask Questions (ASQ):Implementation of a Communication Intervention
|
N/A | |
| Completed |
NCT01722903 -
Detection of CTCs in Patients Undergoing Surgery for Stage IV Colorectal Cancer
|
N/A |